Mana.bio leverages Artificial Intelligence (AI)/ Machine Learning (ML) to design novel non-viral ex-liver cell-specific RNA delivery solutions. Mana Bio is a biotech start-up leveraging data, machine learning, and high throughput screening to design novel LNPs for extrahepatic delivery of nucleic acid therapeutics and vaccines. Mana was founded by a team of serial entrepreneurs and highly regarded experts in the fields of drug delivery, machine learning, and software development.
Mana built predictive AI models and achieved novel IP-protected in vivo results, including lung-specific delivery of mRNA. The company is now open to leveraging this technology platform for collaborations with biotech and pharma companies to optimize formulations for cell-specific delivery of a wide range of payloads, including mRNA and CRISPR gRNA.